RepurpOS

Endometriosis

Disease intelligence for Endometriosis: 116 alterations and 477 ranked therapeutics from curated public databases.

US DALYs820.9KWHO GHE 2021 · all ages
Global DALYs27.02MWHO GHE 2021 · worldwide
Global mortality7,743 deaths/yrWHO GHE 2021 · worldwide
NIH funding$37MFY2025 · RCDC estimate
Funding levelSeverely Underfunded
Spontaneous remissionEndometriosis lesions may partially regress after menopause; spontaneous resolution of symptoms rare; recurrence rate…
Best-intervention remissionExcision surgery achieves pain relief in 60-80% at 6 months but 50% recurrence at 5 years; GnRH agonists + add-back…
Gap sizeVery large — diagnostic delay averages 7-10 years from symptom onset; no disease-modifying treatment; high recurrence…
Primary barrierbiological + practice
Full remission profile →

Disease overview

Alterations
116
Molecular (A)
100
Clinical (B–E)
16
Direct drugs
90
Via biomarker
387
Natural agents
0
Natural products
81
Merged ranked
477
With trial/literature evidence
25

Sources: Open Targets, HPO, ClinicalTrials.gov, DGIdb, ChEMBL, PubMed Literature, GreenMedInfo, Examine.com · Pipeline phase 7 · Updated 2026-07-06

Remission & chronicity

Spontaneous remission
Endometriosis lesions may partially regress after menopause; spontaneous resolution of symptoms rare; recurrence rate after surgery 20-40% at 2 years and 50-60% at 5 years
Best-intervention remission
Excision surgery achieves pain relief in 60-80% at 6 months but 50% recurrence at 5 years; GnRH agonists + add-back therapy: 70-90% pain reduction but oestrogen-deprivation side effects; combined OCP: 50-60% pain reduction; elagolix (Orilissa): 43% reduction in dysmenorrhoea vs placebo (ELARIS EM-I)
Drug-free remission
Relapse after remission
Chronicity
Gap size
Very large — diagnostic delay averages 7-10 years from symptom onset; no disease-modifying treatment; high recurrence after surgery
Primary barrier
biological + practice
Barrier detail: Diagnostic delay of 7-10 years is the largest modifiable factor; endometriosis dismissed as 'normal period pain'; no non-surgical diagnostic test; all medical treatments are suppressive not curative; recurrence after surgery is universal without continued medical suppression

Last SoC change: 2023 — linzagolix (Yselty, GnRH antagonist) approved in Europe; 2021 relugolix combination (Myfembree) FDA approved; elagolix (Orilissa) 2018; GnRH agonists standard since 1980s; excision surgery approach unchanged for decades

Remission data layers: disease_db_100 · source-locked manual data · confidence: high

Identifiers: MONDO: MONDO:0005133

Alterations

Showing 80 of 116 · Types A (molecular) through E (functional)

NameTypeSubtypeDirection FrequencyEvidenceSourcesLinks
ABO
ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase
Molecular Gene Emerging Open Targets
AKT1
AKT serine/threonine kinase 1
Molecular Gene Emerging Open Targets
AMER1
APC membrane recruitment protein 1
Molecular Gene Emerging Open Targets
AMH dosage Lab / Clinical Lab value Emerging ClinicalTrials.gov
AMH level Lab / Clinical Lab value Emerging ClinicalTrials.gov
APOH
apolipoprotein H
Molecular Gene Emerging Open Targets
AR
androgen receptor
Molecular Gene Emerging Open Targets
ARHGAP26
Rho GTPase activating protein 26
Molecular Gene Emerging Open Targets
ARID1A
AT-rich interaction domain 1A
Molecular Gene Emerging Open Targets
ARID2
AT-rich interaction domain 2
Molecular Gene Emerging Open Targets
ARL14EP
ARF like GTPase 14 effector protein
Molecular Gene Emerging Open Targets
AUTS2
activator of transcription and developmental regulator AUTS2
Molecular Gene Emerging Open Targets
Acceptability of menstrual health and endometriosis education (quantitative) Lab / Clinical Lab value Emerging ClinicalTrials.gov
CARD11
caspase recruitment domain family member 11
Molecular Gene Emerging Open Targets
CCDC170
coiled-coil domain containing 170
Molecular Gene Emerging Open Targets
CD109
CD109 molecule
Molecular Gene Emerging Open Targets
CDC42
cell division cycle 42
Molecular Gene Emerging Open Targets
CDKN2B
cyclin dependent kinase inhibitor 2B
Molecular Gene Emerging Open Targets
CEP112
centrosomal protein 112
Molecular Gene Emerging Open Targets
CNR1
cannabinoid receptor 1
Molecular Gene Emerging Open Targets
CREBBP
CREB binding lysine acetyltransferase
Molecular Gene Emerging Open Targets
CTCF
CCCTC-binding factor
Molecular Gene Emerging Open Targets
CTNNB1
catenin beta 1
Molecular Gene Emerging Open Targets
Complication rate Lab / Clinical Lab value Emerging ClinicalTrials.gov
DDR2
discoidin domain receptor tyrosine kinase 2
Molecular Gene Emerging Open Targets
DENND1B
DENN domain containing 1B
Molecular Gene Emerging Open Targets
DIAPH3
diaphanous related formin 3
Molecular Gene Emerging Open Targets
DISC1
DISC1 scaffold protein
Molecular Gene Emerging Open Targets
DLEU7
deleted in lymphocytic leukemia 7
Molecular Gene Emerging Open Targets
DMRTA1
DMRT like family A1
Molecular Gene Emerging Open Targets
DNM3
dynamin 3
Molecular Gene Emerging Open Targets
EEFSEC
eukaryotic elongation factor, selenocysteine-tRNA specific
Molecular Gene Emerging Open Targets
ESR1
estrogen receptor 1
Molecular Gene Emerging Open Targets
ETAA1
ETAA1 activator of ATR kinase
Molecular Gene Emerging Open Targets
ETV6
ETS variant transcription factor 6
Molecular Gene Emerging Open Targets
Endometrioma recurrence Lab / Clinical Lab value Emerging ClinicalTrials.gov
Evaluation of the ovarian reserve by ultrasound by CFA Lab / Clinical Lab value Emerging ClinicalTrials.gov
FGD6
FYVE, RhoGEF and PH domain containing 6
Molecular Gene Emerging Open Targets
FGFR4
fibroblast growth factor receptor 4
Molecular Gene Emerging Open Targets
FOXP1
forkhead box P1
Molecular Gene Emerging Open Targets
FRMD7
FERM domain containing 7
Molecular Gene Emerging Open Targets
FSHB
follicle stimulating hormone subunit beta
Molecular Gene Emerging Open Targets
FSHR
follicle stimulating hormone receptor
Molecular Gene Emerging Open Targets
GDAP1
ganglioside induced differentiation associated protein 1
Molecular Gene Emerging Open Targets
GNRH1
gonadotropin releasing hormone 1
Molecular Gene Emerging Open Targets
GNRHR
gonadotropin releasing hormone receptor
Molecular Gene Emerging Open Targets
GPNMB
glycoprotein nmb
Molecular Gene Emerging Open Targets
GREB1
growth regulating estrogen receptor binding 1
Molecular Gene Emerging Open Targets
GRIN1
glutamate ionotropic receptor NMDA type subunit 1
Molecular Gene Emerging Open Targets
HEY2
hes related family bHLH transcription factor with YRPW motif 2
Molecular Gene Emerging Open Targets
HNF1A
HNF1 homeobox A
Molecular Gene Emerging Open Targets
HOXA10
homeobox A10
Molecular Gene Emerging Open Targets
ID4
inhibitor of DNA binding 4
Molecular Gene Emerging Open Targets
IL1A
interleukin 1 alpha
Molecular Gene Emerging Open Targets
IL7R
interleukin 7 receptor
Molecular Gene Emerging Open Targets
Investigation of the role of Relaxin, Matrix Metalloproteinase-2 and Interleukin 6 in the diagnosis and follow-up of deep infiltrative endometriosis in women with chronic pelvic pain Scales & PROs Clinical scale Emerging ClinicalTrials.gov
JADE2
jade family PHD finger 2
Molecular Gene Emerging Open Targets
KDR
kinase insert domain receptor
Molecular Gene Emerging Open Targets
KRAS
KRas proto-oncogene, GTPase
Molecular Gene Emerging Open Targets
LHCGR
luteinizing hormone/choriogonadotropin receptor
Molecular Gene Emerging Open Targets
MFHAS1
multifunctional ROCO family signaling regulator 1
Molecular Gene Emerging Open Targets
MLH1
mutL homolog 1
Molecular Gene Emerging Open Targets
MLLT10
MLLT10 histone lysine methyltransferase DOT1L cofactor
Molecular Gene Emerging Open Targets
MPPED2
metallophosphoesterase domain containing 2
Molecular Gene Emerging Open Targets
MST1
macrophage stimulating 1
Molecular Gene Emerging Open Targets
MYH11
myosin heavy chain 11
Molecular Gene Emerging Open Targets
NEGR1
neuronal growth regulator 1
Molecular Gene Emerging Open Targets
NF1
neurofibromin 1
Molecular Gene Emerging Open Targets
NFE2L3
NFE2 like bZIP transcription factor 3
Molecular Gene Emerging Open Targets
NFILZ
NFIL3 like basic leucine zipper
Molecular Gene Emerging Open Targets
NGF
nerve growth factor
Molecular Gene Emerging Open Targets
NOTCH1
notch receptor 1
Molecular Gene Emerging Open Targets
NOTCH2
notch receptor 2
Molecular Gene Emerging Open Targets
NR3C1
nuclear receptor subfamily 3 group C member 1
Molecular Gene Emerging Open Targets
NR3C2
nuclear receptor subfamily 3 group C member 2
Molecular Gene Emerging Open Targets
NUTM2B
NUT family member 2B
Molecular Gene Emerging Open Targets
Number of Participants with Pregnancy Lab / Clinical Lab value Emerging ClinicalTrials.gov
Number of participants with maximum severity of TEAEs (Part A) Lab / Clinical Lab value Emerging ClinicalTrials.gov
OPRK1
opioid receptor kappa 1
Molecular Gene Emerging Open Targets
OPRM1
opioid receptor mu 1
Molecular Gene Emerging Open Targets

Therapeutics

Direct disease associations, biomarker-linked drugs, OSMF narrative-review natural agents, merged ranking, and clinical trial / literature evidence (top agents)

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing Small molecule Approved Strong 95 DGIdb
ABIRATERONE ACETATE Repurposing Small molecule Approved Strong 95 DGIdb
ACETAZOLAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
ACETOPHENAZINE Repurposing Small molecule Approved Strong 95 DGIdb
AFATINIB Repurposing Small molecule Approved Strong 95 DGIdb
ALCLOFENAC Repurposing Small molecule Approved Strong 95 DGIdb
ALCLOMETASONE DIPROPIONATE Repurposing Small molecule Approved Strong 95 DGIdb
AMCINONIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMDINOCILLIN Repurposing Small molecule Approved Strong 95 DGIdb
AMIODARONE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
AMLEXANOX Repurposing Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing Small molecule Approved Strong 95 ChEMBL
ANHYDROUS TACROLIMUS Repurposing Small molecule Approved Strong 95 DGIdb
APALUTAMIDE Repurposing Small molecule Approved Strong 95 DGIdb
APOMORPHINE Repurposing Small molecule Approved Strong 95 DGIdb
APREMILAST Repurposing Small molecule Approved Strong 95 DGIdb
ASTEMIZOLE Repurposing Small molecule Approved Strong 95 DGIdb
ATALUREN Repurposing Small molecule Approved Strong 95 DGIdb
ATEZOLIZUMAB Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
ATRACURIUM BESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
ATROPINE Repurposing Small molecule Approved Strong 95 DGIdb
AZACITIDINE Repurposing Small molecule Approved Strong 95 DGIdb
AZARIBINE Repurposing Small molecule Approved Strong 95 DGIdb
BECLOMETHASONE DIPROPIONATE Repurposing Small molecule Approved Strong 95 DGIdb
BENAZEPRIL HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
BENORILATE Repurposing Small molecule Approved Strong 95 DGIdb
BETAMETHASONE Repurposing Small molecule Approved Strong 95 DGIdb
BETAMETHASONE DIPROPIONATE Repurposing Small molecule Approved Strong 95 DGIdb
BETAMETHASONE SODIUM PHOSPHATE Repurposing Small molecule Approved Strong 95 DGIdb
BETAMETHASONE VALERATE Repurposing Small molecule Approved Strong 95 DGIdb
BICALUTAMIDE Repurposing Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
BICALUTAMIDE Repurposing Small molecule Approved Strong 95 ChEMBL
BIFONAZOLE Repurposing Small molecule Approved Strong 95 DGIdb
BISACODYL Repurposing Small molecule Approved Strong 95 DGIdb
BITHIONOL Repurposing Small molecule Approved Strong 95 DGIdb
BITHIONOLATE SODIUM Repurposing Small molecule Approved Strong 95 DGIdb
BORTEZOMIB Repurposing Small molecule Approved Strong 95 DGIdb
BROMOCRIPTINE Repurposing Small molecule Approved Strong 95 DGIdb
BROMOCRIPTINE MESYLATE Repurposing Small molecule Approved Strong 95 DGIdb
BUPRENORPHINE HYDROCHLORIDE Repurposing Small molecule Approved Strong 95 DGIdb
BUTAMBEN Repurposing Small molecule Approved Strong 95 DGIdb
CAFFEINE Repurposing Small molecule Approved Strong 95 DGIdb
CALCIFEDIOL ANHYDROUS Repurposing Small molecule Approved Strong 95 DGIdb
CALCIPOTRIENE Repurposing Small molecule Approved Strong 95 DGIdb
CALCITRIOL Repurposing Small molecule Approved Strong 95 DGIdb
CANDESARTAN CILEXETIL Repurposing Small molecule Approved Strong 95 DGIdb
CANRENONE Repurposing Small molecule Approved Strong 95 DGIdb
CAPIVASERTIB Repurposing Small molecule Approved Strong 95 DGIdb
CARBACHOL Repurposing Small molecule Approved Strong 95 ChEMBL
DrugTypePhaseEvidence ScoreSourcesLinks
ASOPRISNIL Small molecule Phase III Moderate 80 Open Targets
CANNABIDIOL Small molecule Phase III Moderate 80 Open Targets
CHORIOGONADOTROPIN ALFA Biologic Phase III Moderate 80 Open Targets
CYPROTERONE ACETATE Small molecule Phase III Moderate 80 Open Targets
DEGARELIX Biologic Phase III Moderate 80 Open Targets
DYDROGESTERONE Small molecule Phase III Moderate 80 Open Targets
ELAGOLIX Small molecule Phase III Moderate 80 Open Targets
ESKETAMINE Small molecule Phase III Moderate 80 Open Targets
ESTRADIOL Small molecule Phase III Moderate 80 Open Targets
GONADORELIN Biologic Phase III Moderate 80 Open Targets
GONADORELIN ACETATE Biologic Phase III Moderate 80 Open Targets
GONADOTROPIN, CHORIONIC Biologic Phase III Moderate 80 Open Targets
INDOLE-3-CARBINOL Small molecule Phase III Moderate 80 Open Targets
LEUPROLIDE Biologic Phase III Moderate 80 Open Targets
LEUPROLIDE ACETATE Biologic Phase III Moderate 80 Open Targets
LEVONORGESTREL Small molecule Phase III Moderate 80 Open Targets
LINZAGOLIX Small molecule Phase III Moderate 80 Open Targets
MENOTROPINS Biologic Phase III Moderate 80 Open Targets
NALTREXONE Small molecule Phase III Moderate 80 Open Targets
PENTOXIFYLLINE Small molecule Phase III Moderate 80 Open Targets
PROGESTERONE Small molecule Phase III Moderate 80 Open Targets
RELUGOLIX Small molecule Phase III Moderate 80 Open Targets
SEGESTERONE Small molecule Phase III Moderate 80 Open Targets
SEGESTERONE ACETATE Small molecule Phase III Moderate 80 Open Targets
TRIPTORELIN Biologic Phase III Moderate 80 Open Targets
TRIPTORELIN ACETATE Biologic Phase III Moderate 80 Open Targets
TRIPTORELIN PAMOATE Biologic Phase III Moderate 80 Open Targets
ANASTROZOLE Small molecule Phase II Emerging 60 Open Targets
ASCORBIC ACID Small molecule Phase II Emerging 60 Open Targets
ATOSIBAN Biologic Phase II Emerging 60 Open Targets
BENTAMAPIMOD Small molecule Phase II Emerging 60 Open Targets
CABERGOLINE Small molecule Phase II Emerging 60 Open Targets
CETRORELIX Biologic Phase II Emerging 60 Open Targets
ELIAPIXANT Small molecule Phase II Emerging 60 Open Targets
ESTROGEN Small molecule Phase II Emerging 60 Open Targets
ESTROGENS, CONJUGATED Small molecule Phase II Emerging 60 Open Targets
ETONOGESTREL Small molecule Phase II Emerging 60 Open Targets
FILGRASTIM Biologic Phase II Emerging 60 Open Targets
GESTRINONE Small molecule Phase II Emerging 60 Open Targets
INFLIXIMAB Biologic Phase II Emerging 60 Open Targets
DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
3,3',4',5-TETRACHLOROSALICYLANILIDE Repurposing via AR Small molecule Approved Strong 95 DGIdb
ABIRATERONE ACETATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
ACETAZOLAMIDE Repurposing via ABO Small molecule Approved Strong 95 ChEMBL
ACETOPHENAZINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AFATINIB Repurposing via AKT1 Small molecule Approved Strong 95 DGIdb
ALCLOFENAC Repurposing via AR Small molecule Approved Strong 95 DGIdb
ALCLOMETASONE DIPROPIONATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMCINONIDE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMDINOCILLIN Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMIODARONE HYDROCHLORIDE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMLEXANOX Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMLODIPINE BESYLATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AMPHETAMINE Repurposing via ABO Small molecule Approved Strong 95 ChEMBL
ANHYDROUS TACROLIMUS Repurposing via AR Small molecule Approved Strong 95 DGIdb
APALUTAMIDE Repurposing via AR Small molecule Approved Strong 95 DGIdb
APOMORPHINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
APREMILAST Repurposing via CDKN2B Small molecule Approved Strong 95 DGIdb
ASTEMIZOLE Repurposing via AR Small molecule Approved Strong 95 DGIdb
ATALUREN Repurposing via AR Small molecule Approved Strong 95 DGIdb
ATEZOLIZUMAB Repurposing via ARID1A Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
ATRACURIUM BESYLATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
ATROPINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AZACITIDINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
AZARIBINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BECLOMETHASONE DIPROPIONATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BENAZEPRIL HYDROCHLORIDE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BENORILATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BETAMETHASONE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BETAMETHASONE DIPROPIONATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BETAMETHASONE SODIUM PHOSPHATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BETAMETHASONE VALERATE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BICALUTAMIDE Repurposing via AR Small molecule Approved Strong 95
No indexed hits
View evidence
DGIdb
BICALUTAMIDE Repurposing via ABO Small molecule Approved Strong 95 ChEMBL
BIFONAZOLE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BISACODYL Repurposing via AR Small molecule Approved Strong 95 DGIdb
BITHIONOL Repurposing via AR Small molecule Approved Strong 95 DGIdb
BITHIONOLATE SODIUM Repurposing via AR Small molecule Approved Strong 95 DGIdb
BORTEZOMIB Repurposing via AR Small molecule Approved Strong 95 DGIdb
BROMOCRIPTINE Repurposing via AR Small molecule Approved Strong 95 DGIdb
BROMOCRIPTINE MESYLATE Repurposing via AR Small molecule Approved Strong 95 DGIdb

Natural Products

81 natural products with the same evidence schema as repurposed drugs — registry trials, PubMed literature, and reference links (pipeline-ranked)

Reference lookups: GreenMedInfo · Examine.com

DrugTypePhaseEvidence ScoreTrials & literatureSourcesLinks
Vitamin D3 Natural product Nutraceutical Approved Moderate 20
4 trials 1 Trial pubs
View evidence

Registry trials

  • NCT00654524 — Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis (UNKNOWN) PHASE4
  • NCT02393482 — Psychological Impact of Amenorrhea in Women With Endometriosis (UNKNOWN) PHASE4
  • NCT06289257 — Analysis of Vitamin D and VDR Expression in Endometriosis: A Case-Control Study (COMPLETED)
  • NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4

Published literature

Examine.com, GreenMedInfo
Omega-3 Fatty Acids Natural product Nutraceutical Approved Moderate 20
1 trials 1 Meta-analysis
View evidence

Registry trials

  • NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4

Published literature

Examine.com, GreenMedInfo
Vitamin D3 Natural product Nutraceutical Approved Emerging 19
4 trials 1 Trial pubs
View evidence

Registry trials

  • NCT00654524 — Randomized Study of Gonadotropin-releasing-hormone Agonist (GnRH-a) or Expectant Management for Endometriosis (UNKNOWN) PHASE4
  • NCT02393482 — Psychological Impact of Amenorrhea in Women With Endometriosis (UNKNOWN) PHASE4
  • NCT06289257 — Analysis of Vitamin D and VDR Expression in Endometriosis: A Case-Control Study (COMPLETED)
  • NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4

Published literature

Examine.com
Melatonin Natural product Nutraceutical Phase II Moderate 17
2 trials 4 Cochrane 4 RCT
View evidence

Registry trials

  • NCT03782740 — Effect of Melatonin on Reduction of Pelvic Pain (COMPLETED) PHASE2
  • NCT05298657 — The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment (UNKNOWN)

Published literature

Examine.com, GreenMedInfo
Omega-3 Fatty Acids Natural product Nutraceutical Approved Emerging 13
1 trials 1 Meta-analysis
View evidence

Registry trials

  • NCT02387931 — Supplementation in Adolescent Girls With Endometriosis (COMPLETED) PHASE4

Published literature

Examine.com
Melatonin Natural product Nutraceutical Phase II Emerging 13
2 trials 4 Cochrane 4 RCT
View evidence

Registry trials

  • NCT03782740 — Effect of Melatonin on Reduction of Pelvic Pain (COMPLETED) PHASE2
  • NCT05298657 — The Angiotensin-Melatonin Axis in Poor and Hyper Responders for IVF Treatment (UNKNOWN)

Published literature

Examine.com
Vitamin C Natural product Nutraceutical Preclinical Emerging 10
4 RCT
View evidence
GreenMedInfo
Vitamin E Natural product Nutraceutical Phase II Emerging 10
1 trials 4 Meta-analysis 4 Trial pubs
View evidence

Registry trials

  • NCT02058212 — Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI) (COMPLETED) PHASE2

Published literature

GreenMedInfo
N-Acetylcysteine Natural product Amino acid Phase III Emerging 10
1 trials 2 Trial pubs
View evidence

Registry trials

  • NCT05460858 — NAC Effect on Infertile Women With Endometrioma (UNKNOWN) PHASE3

Published literature

GreenMedInfo
Zinc Natural product Nutraceutical Phase II Emerging 10
1 trials 1 Trial pubs
View evidence

Registry trials

  • NCT02058212 — Use of Antioxidant in Endometriotic Women to Improve Intracytoplasmic Sperm Injection (ICSI) (COMPLETED) PHASE2

GreenMedInfo
Ginger Natural product Botanical Preclinical Emerging 10
1 Cochrane
View evidence

Published literature

GreenMedInfo
Vitamin K Natural product Nutraceutical Preclinical Emerging 10
No indexed hits
View evidence
GreenMedInfo
Resveratrol Natural product Food compound Approved Emerging 7
1 trials
View evidence

Registry trials

  • NCT02475564 — Resveratrol for Pain Due to Endometriosis (COMPLETED) PHASE4

GreenMedInfo
Curcumin Natural product Food compound Preclinical Emerging 7
2 trials 3 Trial pubs 3 RCT
View evidence

Registry trials

  • NCT03016039 — Curcumin Supplementation for Gynecological Diseases (UNKNOWN) NA
  • NCT04150406 — Flexofytol® for the Treatment of Endometriosis- Associated Pain (UNKNOWN) NA

GreenMedInfo
Quercetin Natural product Food compound Preclinical Emerging 7
1 trials
View evidence

Registry trials

  • NCT05983224 — Effect of Quercetin Supplementation on Endometriosis Outcomes (UNKNOWN) NA

Published literature

GreenMedInfo
Feverfew Natural product Botanical Preclinical Emerging 7
No indexed hits
View evidence
GreenMedInfo
Boswellia Natural product Botanical Preclinical Emerging 7
2 pubs
View evidence
GreenMedInfo
Egcg Natural product Food compound Phase II Emerging 7
1 trials
View evidence

Registry trials

  • NCT02832271 — Green Tea Extract for Endometriosis Treatment (COMPLETED) PHASE2

GreenMedInfo
Alpha-Lipoic Acid Natural product Nutraceutical Preclinical Emerging 7
2 Cochrane
View evidence

Published literature

GreenMedInfo
Probiotics Natural product Probiotic Phase II Emerging 7
4 trials 3 RCT
View evidence

Registry trials

  • NCT07149519 — Impact of Dietary Guidance and Probiotics in the Treatment of Endometriosis and Irritable Bowel Syndrome in Women (RECRUITING) NA
  • NCT06929364 — The Role of Probiotics in the Treatment of Endometriosis (ProMetrioS): a Randomised Double-blinded Placebo-controlled Cross-over Trial (RECRUITING) NA
  • NCT06592976 — Effects of a Multi-strain Oral Probiotic on the Vaginal Microbiota Composition in Healthy Women and Women with Endometriosis (ACTIVE_NOT_RECRUITING) NA
  • NCT04955574 — Probiotic and Antibiotic Therapies in Women With Unexplained Infertility (WITHDRAWN) PHASE2

GreenMedInfo
Selenium Natural product Nutraceutical Preclinical Emerging 7 GreenMedInfo
Silymarin Natural product Botanical Preclinical Emerging 7 GreenMedInfo
Sulforaphane Natural product Food compound Preclinical Emerging 7 GreenMedInfo
Licorice Natural product Botanical Preclinical Emerging 2 GreenMedInfo
EGCG (Epigallocatechin Gallate) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Polyphenols Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Ginsenosides Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Flavonoids Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Vitamin a Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Xanthohumol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Fruit: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Vegetables: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Astaxanthin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Antioxidant Formulas Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Progesterone Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Garlic: Aged Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Nettle Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Genistein Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Apigenin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Catechin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Naringenin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Pterostilbene Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Puerarin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Cryptoxanthin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Emodin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Homeopathic Medicine: All Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Ginseng (Siberian) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Formononetin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
6-Shogaol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Acai Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Aloe Vera Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Luteolin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Bufalin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Bee Propolis Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Caffeic Acid Phenethyl Ester Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Cat's Claw Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Hesperidin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Fisetin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Kaempferol Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Fucoidan Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Honokiol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Indole-3-Carbinol Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Leonurine Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Myricetin Natural product Food compound Preclinical Emerging 0 GreenMedInfo
Oleuropein Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Palmitoylethanolamide Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Royal Jelly Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Sea Buckthorn Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
St. John's Wort Natural product Botanical Preclinical Emerging 0 GreenMedInfo
Silibinin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Sinomenine Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Propolis: Bee Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Broccoli Sprouts Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Black Tea Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Theaflavins Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Raspberry Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Yellow Sweet Clover (Melilotus Officinalis) Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Hydrogen: Molecular Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Nobiletin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo
Vanillin Natural product Nutraceutical Preclinical Emerging 0 GreenMedInfo

Alterations and therapeutics are aggregated from public databases (Open Targets, HPO, ChEMBL, DGIdb, and others). Natural agents are candidates from OSMF narrative reviews on opensourcemed.info/chronic-disease.html — not approved treatments. This page is for research orientation only — not medical advice.

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
VitalScan4PACVS Remote physiological monitoring study for post-acute COVID-19 vaccination syndrome.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.